Showing 2811-2820 of 5646 results for "".
- Zeiss Develops Multifunctional Smart Glasshttps://modernod.com/news/zeiss-develops-multifunctional-smart-glass/2476327/For the first time, a technology developed by Zeiss has made it possible to utilize transparent glass or plastic in a whole range of different ways, according to a company news release. The see-through surfaces with integrated, invisible microstructured optics permit a range of different applicat
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- Study: Scleral Lenses Coated with Tangible Hydra-PEG Improve Dry Eye Symptoms, Comforthttps://modernod.com/news/study-scleral-lenses-coated-with-tangible-hydra-peg-improve-dry-eye-symptoms-comfort/2476344/Tangible Science announced that a
- Statement From FDA Leadership On a Record Year for Device Innovationhttps://modernod.com/news/statement-from-fda-leadership-on-a-record-year-for-device-innovation/2479598/FDA Commissioner Scott Gottlieb, MD, and Jeff Shuren, MD, director for the Center for Devices and Radiological Health, released the following statement addressing a record year for device innovation: “The FDA’s focus on both safety and innovation stems from our historic mission
- MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF for Ophthalmic Diseaseshttps://modernod.com/news/manf-therapeutics-receives-notice-of-allowance-from-us-patent-trademark-office-covering-the-use-of-manf-or-cdnf-for-ophthalmic-diseases/2476184/MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, is in preclinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases. On Tuesday, the
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for the Treatment of Postoperative Inflammationhttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-the-treatment-of-postoperative-inflammation/2476198/Ocular Therapeutix announced the submission of a supplemental new drug application (NDA) to the FDA for Dextenza (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. The
- CVP Partners With Northwest and Central Ohio Ophthalmology Practicehttps://modernod.com/news/cvp-partners-with-northwest-and-central-ohio-ophthalmology-practice/2476202/CEI Vision Partners (CVP) announced that Retina Vitreous Associates (RVA) of Toledo, Ohio is now the newest partner practice to join the CVP platform. RVA is a vitreoretinal surgical practice with nine ophthalmologists who specialize in medical and surgical
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr
- Exonate Closes £1.5 Million Fundraising Accelerate Development Eye Drop Treatment for Retinal Neovascular Diseaseshttps://modernod.com/news/exonate-closes-1-5-million-fundraising-accelerate-development-eye-drop-treatment-for-retinal-neovascular-diseases/2476222/Exonate announces the successful closing of its fourth financing round, raising £1.5 million. The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases. The company continues to make substantial progress an
- EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019https://modernod.com/news/eyepoint-pharmaceuticals-to-launch-dexycu-and-yutiq-in-first-quarter-of-2019/2476226/During a corporate update, EyePoint Pharmaceuticals executives said they expect to launch both Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of calendar 2019. “EyePoint has made significant progress in